Edwards Lifesciences : Gets FDA OK for Konect Resilia Aortic Valved Conduit

By Colin Kellaher

Edwards Lifesciences Corp. Wednesday said the U.S. Food and Drug Administration approved its Konect Resilia aortic valved conduit for complex aortic-valve surgeries.

The Irvine, Calif., company said the product is the first ready-to-implant solution for bio-Bentall procedures, which involve replacement of a patient's aortic valve, aortic root and the ascending aorta.

Edwards said the device can streamline treatment for patients requiring the complex and technical surgery, noting that up to 30% of Bentall procedures are performed in an emergency setting.

Write to Colin Kellaher at [e-mail]